Aethlon Medical Reports Q1 2025 Financial Results

Aethlon ( (AEMD) ) has released its Q1 earnings. Here is a breakdown of the information Aethlon presented to its investors.

Aethlon Medical, Inc., a clinical-stage medical device company headquartered in San Diego, focuses on developing the Hemopurifier to address unmet needs in oncology and infectious diseases by selectively removing pathogenic targets from biologic fluids.

In its latest earnings report, Aethlon Medical announced financial results for the fiscal first quarter ending June 30, 2025, highlighting significant progress in its Australian cancer trial and a notable reduction in operating expenses by 32%. The company also shared advancements in its Long COVID research collaboration with UCSF.

Key financial metrics include a decrease in operating expenses to $1.8 million from $2.6 million in the previous year, driven by reductions in payroll, professional fees, and administrative costs. The Australian Hemopurifier cancer trial showed promising results with no serious adverse events, and the company expanded patient eligibility for future cohorts. Aethlon also decided to focus resources on the Australian trial, opting out of a similar trial in India due to timeline and strategic considerations.

The Hemopurifier demonstrated 98.5% removal of platelet-derived extracellular vesicles in preclinical studies, suggesting potential broader applications in other diseases. The company remains committed to advancing the Hemopurifier toward regulatory approval and exploring its utility across multiple disease areas.

Looking ahead, Aethlon Medical aims to continue its clinical progress and operational efficiency, with a focus on generating timely data to support a potential Premarket Approval trial for the Hemopurifier.